financetom
Business
financetom
/
Business
/
C3.ai Delivers Good Fiscal Q1 With 'Some Spots of Weakness,' Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
C3.ai Delivers Good Fiscal Q1 With 'Some Spots of Weakness,' Wedbush Says
Sep 5, 2024 8:49 AM

11:22 AM EDT, 09/05/2024 (MT Newswires) -- C3.ai ( AI ) delivered good fiscal Q1 results and reaffirmed its fiscal 2025 revenue guidance, though there were "some spots of weakness," Wedbush Securities said Thursday.

Late Wednesday, the company reported fiscal Q1 financial results that surpassed Wall Street's estimates. C3.ai ( AI ) reaffirmed its fiscal 2025 revenue guidance of $370 million to $395 million.

While the company expects to generate negative free cash flow in fiscal Q2 and Q3, it reaffirmed its outlook to generate positive free cash flow for the full year.

"While this was a slight bump in the road, we remain positive on C3.ai ( AI ) going into 2025 with a strong pipeline across industries coupled with solid top-line growth while seeing solid bottom-line expansion as the AI Revolution gains more momentum over the next few years," Wedbush analysts, including Daniel Ives, said in a note to clients.

The brokerage reduced its price target on the company's stock to $30 from $40 while maintaining its outperform rating.

C3.ai ( AI ) shares were down 14% in recent Thursday trading.

Price: 19.74, Change: -3.27, Percent Change: -14.21

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Contineum Therapeutics Progresses Enrollment for Phase 1b Trial of PIPE-791
Contineum Therapeutics Progresses Enrollment for Phase 1b Trial of PIPE-791
Jun 25, 2025
08:58 AM EDT, 06/25/2025 (MT Newswires) -- Contineum Therapeutics ( CTNM ) said Wednesday it has completed enrollment of healthy volunteer and progressive multiple sclerosis cohorts for its phase 1b trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 receptor. The screening and enrollment of idiopathic pulmonary fibrosis patients for the trial is ongoing, the company said. The...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Jun 25, 2025
June 25 (Reuters) - Gilead Sciences ( GILD ) has entered into an option and license deal with Kymera Therapeutics ( KYMR ) to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the deal, Gilead would pay as much as $750 million, including up to $85 million upfront, in...
OpenAI says China's Zhipu AI gaining ground amid Beijing's global AI push
OpenAI says China's Zhipu AI gaining ground amid Beijing's global AI push
Jun 25, 2025
(Reuters) -OpenAI said on Wednesday its analysts have seen notable progress by Chinese start-up Zhipu AI in securing government contracts across several regions, signaling China's growing momentum in pursuing global AI leadership. Zhipu AI, which is backed by the Chinese Communist Party, aims to lock Chinese systems and standards into emerging markets before U.S. or European rivals can, while showcasing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved